Brain Organoids Models of Human Brain Derived from Stem Cells

Viren Sanganpanich^*
*Correspondence: Viren Sanganpanich, Department of Psychiatry, Mahidol University, Bangkok, Thailand, Email:

Keywords

Biospecimens • Brain organoid • Brain tissue • Neurological disorders

Introduction

In the context of brain organoid research, obtaining informed consent from donors is crucial due to the highly sensitive nature of the research and the potential implications it holds for donors, their families, and society at large. Donors must be adequately informed about the purpose of the research, the procedures involved, the potential risks and benefits, and how their biospecimens will be used in brain organoid studies. Ensuring that donors comprehend the complexities of the research is essential in upholding their autonomy and respecting their rights. Understanding the perspectives of donors is essential in shaping ethical practices in brain organoid research. Donors may have diverse viewpoints influenced by cultural, religious, and personal beliefs. Some donors may view contributing biospecimens for scientific research as a way to advance medical knowledge and potentially find cures for debilitating brain disorders. Others may harbor concerns about privacy, the potential misuse of their genetic information, or the commodification of their biospecimens. Acknowledging and addressing these concerns is vital in fostering trust between researchers and donors. Brain organoid research presents unique ethical challenges, including concerns about the consciousness and moral status of the organoids, the appropriate use of brain tissue, and the potential for unintended consequences, such as creating organoids with enhanced cognitive abilities. Additionally, questions arise about the ownership and commercialization of research findings derived from brain organoids [1].

Literature Review

Striking a balance between scientific advancement and ethical principles requires ongoing dialogue between researchers, ethicists, policymakers, and the public. Looking ahead, it is imperative to establish clear guidelines and regulations governing brain organoid research. Transparency, open communication, and continuous engagement with the public can help demystify the research process and address donor concerns. Researchers must also consider the long-term implications of their work, including the potential societal impact and the responsible dissemination of research findings. Collaborative efforts between scientists, ethicists, and policymakers are essential in developing ethical frameworks that protect donor rights, ensure scientific progress, and uphold the integrity of brain organoid research. Brain organoid research holds immense promise for advancing our understanding of the human brain and developing innovative treatments for neurological disorders. However, navigating the ethical complexities surrounding the acquisition and use of biospecimens requires careful consideration of donor perspectives, informed consent, and broader ethical implications. By actively involving donors in the dialogue, addressing their concerns, and upholding the principles of informed consent, the scientific community can pave the way for responsible and ethical brain organoid research that benefits humanity as a whole. In recent years, advances in biotechnology have led to groundbreaking research in the field of neuroscience, particularly in the development of brain organoids [2].

Discussion

These miniature, three-dimensional models of the human brain hold immense promise for understanding neurological diseases, drug testing, and personalized medicine. However, the ethical implications of using human biospecimens for brain organoid research, and the informed consent process involved, have come under scrutiny. This essay delves into the donor perspectives on informed consent and the use of biospecimens for brain organoid research, highlighting the need for transparency, respect for autonomy, and ethical considerations in this evolving field. Brain organoids, often referred to as "mini-brains," are generated from human pluripotent stem cells and have the potential to replicate certain aspects of human brain development. These tiny structures mimic the cellular organization and function of the brain, making them invaluable tools for studying neural development, disease pathology, and drug screening. Researchers can use brain organoids to investigate conditions like Alzheimer's, Parkinson's, and autism spectrum disorders, which are notoriously complex and difficult to study in animal models. As brain organoid research advances, it has the potential to revolutionize our understanding of brain-related diseases and the development of therapies. However, this progress is not without its ethical challenges, particularly regarding the sourcing of human biospecimens for this research [3].

Informed consent is the cornerstone of ethical research involving human subjects. It ensures that individuals voluntarily participate in research projects with full knowledge of the potential risks, benefits, and implications. Obtaining informed consent is especially crucial when dealing with biospecimens for brain organoid research due to the intimate nature of the material involved. Donors, in this context, refer to individuals who provide biological samples, such as skin cells or blood, for the generation of stem cells used in brain organoid research. These donors may be patients, research participants, or individuals who voluntarily donate their samples to advance scientific knowledge. One fundamental aspect of informed consent is respecting the autonomy of donors. Donors must have the freedom to make decisions about their biological samples without coercion or pressure. However, in the case of brain organoid research, there are unique challenges that may affect donors' autonomy. For instance, patients may be approached for biospecimen donation during a vulnerable time, such as when they are diagnosed with a neurological disorder. This vulnerability can potentially compromise their ability to provide informed consent freely [4].

Researchers and healthcare providers must take special care to ensure that donors are fully informed about the research, and that their decision to participate is entirely voluntary. Another concern in brain organoid research is the potential for the unintentional revelation of donors' identities. While biospecimens are often anonymized to protect donors' privacy, advances in genomics and bioinformatics make it increasingly possible to re-identify individuals based on their genetic information. This raises significant ethical questions about privacy and confidentiality. Donors may be hesitant to participate if they fear that their identity could be disclosed in the future. Researchers and institutions must establish robust safeguards to protect the privacy of donors and reassure them that their personal information will remain confidential. Donors may also desire some degree of control over how their biospecimens are used and who has access to them. They may want to know if their samples are being used exclusively for brain organoid research or if they may be shared with other researchers. This desire for control is not only a matter of respecting autonomy but also of acknowledging the emotional and personal significance of the donation. Research institutions should consider implementing mechanisms for donors to provide feedback and control over the use of their biospecimens, even after they have been donated [5].

Transparent policies and ongoing communication can help build trust between donors and researchers. Brain organoid research can have dual uses, including both therapeutic and potentially harmful applications. While donors may be motivated by the prospect of advancing medical knowledge and finding cures for neurological diseases, they may also worry about unintended consequences, such as the creation of conscious entities with cognitive capabilities resembling humans. Researchers and institutions must address these concerns by ensuring that their work adheres to strict ethical guidelines and is subject to robust oversight. Donors should be informed about these safeguards to alleviate anxieties about misuse. Donors may expect some form of benefit sharing or compensation for their contributions to research, especially if their biospecimens lead to significant discoveries or commercial products. Ethical discussions surrounding benefit sharing in brain organoid research are ongoing, with some arguing for a more equitable distribution of any financial gains. Transparency in the informed consent process is crucial in managing donor expectations regarding benefit sharing. Researchers should clearly communicate how any potential benefits, including financial gains, will be distributed and ensure that donors are comfortable with the arrangements [6].

Conclusion

Donors may also be concerned about the long-term impact of their contributions. Brain organoid research can span many years, and donors may wonder how their biospecimens will be used, stored, and disposed of after the research is completed. Ensuring that donors are well-informed about the research timeline and the fate of their samples can alleviate these concerns. Donor perspectives on informed consent and the use of biospecimens for brain organoid research are multifaceted and deserving of careful consideration. Informed consent processes must prioritize respect for autonomy, privacy, and donor control while addressing ethical concerns like dual-use dilemmas, benefit sharing, and long-term impact. As brain organoid research continues to advance, researchers, healthcare providers, and institutions must work collaboratively to establish and maintain ethical practices that protect donors' interests and uphold the principles of responsible research. By doing so, we can ensure that the potential benefits of brain organoid research are realized while respecting the rights and perspectives of those who make this research possible through their valuable contributions.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Zhou, Yilin, Tim Lekic, Nancy Fathali and Robert P. Ostrowski, et al. "Isoflurane posttreatment reduces neonatal hypoxic–ischemic brain injury in rats by the sphingosine-1-phosphate/phosphatidylinositol-3-kinase/Akt pathway."Stroke41 (2010): 1521-1527.

   Google Scholar, Crossref, Indexed at

2. Nichols, Emma, Cassandra EI Szoeke, Stein Emil Vollset and Nooshin Abbasi, et al. "Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016."Lancet Neurol 18 (2019): 88-106.

   Google Scholar, Crossref, Indexed at

3. Thal, Dietmar R., Estibaliz Capetillo-Zarate, Kelly Del Tredici and Heiko Braak. "The development of amyloid β protein deposits in the aged brain."Sci Aging Knowl Environ 2006 (2006): re1-re1.

   Google Scholar, Crossref, Indexed at

4. Khan, Shahzad S. and George S. Bloom. "Tau: the center of a signaling nexus in Alzheimer's disease."Front Neurosci 10 (2016): 31.

   Google Scholar, Crossref, Indexed at

5. Lin, Yu-Ting, Chiung-Chun Huang and Kuei-Sen Hsu. "Oxytocin promotes long-term potentiation by enhancing epidermal growth factor receptor-mediated local translation of protein kinase Mζ."J Neurosci32 (2012): 15476-15488.

   Google Scholar, Crossref, Indexed at

6. Raam, Tara, Kathleen M. McAvoy, Antoine Besnard and Alexa H. Veenema, et al. "Hippocampal oxytocin receptors are necessary for discrimination of social stimuli."Nat Commun 8 (2017): 2001.

   Google Scholar, Crossref, Indexed at